The Boston R&D Center ribbon-cutting ceremony. From the left, Dr. Youxin Li, Prof. Robert S. Langer and Prof. Guangping Gao.
The Luye Life Sciences Group announced the opening of its new Boston R&D Center, the second global R&D facility set up in the United States. The Boston R&D Center will collaborate with multiple business divisions of the Luye Life Sciences Group including Luye Pharma, Luye Medical, and Luye Diagnostics.
As an integral part of Luye Life Sciences Group's global R&D system, the newly-built Boston R&D Center will focus on international R&D collaboration. Joint efforts between Chinese and U.S. teams will accelerate the research and development of new drug candidates in key disease areas. The Boston R&D Center will act as an important center of excellence to internalize novel early-stage biopharmaceutical assets and disruptive drug delivery technologies.
"The opening of our Boston R&D Center marks another milestone in the Group's exploration of pharmaceuticals," said Dr. Youxin Li, Global R&D President of Luye Pharma Group. "Building on existing R&D platforms for the drug delivery system（DDS）and Mab biosimilars, Luye Pharma is moving towards next-generation biopharmaceutical products and intelligent drug products. With Boston's leading position in the global biopharmaceutical industry, we look forward to laying a solid technical foundation through collaboration on new platforms and projects, to help ensure the sustainable pipeline development of Luye Life Sciences Group."
Several biotechnology companies have already expressed their interest in working with the Boston R&D Center, tracking and analyzing a number of new early-stage drugs and technologies. These projects will effectively promote and strengthen the R&D capabilities of Luye Life Sciences Group in key areas such as cancer, schizophrenia, depression, cardiovascular anomalies, and Parkinson's disease.
Luye Life Sciences Group currently has operations in China, the United States, Europe, Australia, Singapore, South Korea, and Japan. Globally, the Group has 15,000 employees, of which more than 60 percent are from outside of China. The Boston R&D Center will support the Luye Life Sciences Group to accelerate its globalization strategy and realize its vision of becoming one of the most respected global leaders in the healthcare industry through optimization and integration of global R&D resources, international talent recruitment and exchange, and cooperation on various new projects and technologies.